Tevogen Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Apr 29, 2024 and accepted by EDGAR at Apr 26, 2024, 21:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $256.0k | us-gaap:InterestExpense |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$67.3k | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 12 months2023-01-01 to 2023-12-31 | $343.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | At period end2023-12-31 | $355.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $17.0m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $3.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $17.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | −$17.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-24-016796. Last ingested by Listed: Nov 4, 2026, 18:10 ET. Listed shows no prices and gives no investment advice.